Fibrobiologics, INC. (FBLG) — 10-Q Filings

10-Q Filings (6)

• FibroBiologics' Losses Double Amid Soaring R&D, Cash Dwindles — Oct 31, 2025 Risk: high
  FibroBiologics, Inc. (FBLG) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $15.402 million, a substantial ri
• FibroBiologics Posts Zero Revenue, Deepens Losses Amid Equity Raises — Jul 31, 2025 Risk: high
  FibroBiologics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercialization stage. The company incurred
• FibroBiologics Files Q1 2025 10-Q — May 14, 2025 Risk: low
  FibroBiologics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, located at 455 E. Medical Center Blvd, Suite 300, Houston, TX, reported i
• FibroBiologics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  FibroBiologics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial position and operational updates. Key f
• FibroBiologics Files 10-Q, Details Preferred Stock — Aug 7, 2024 Risk: medium
  FibroBiologics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, located in Houston, TX, operates in the Pharmaceutical Preparations sector
• FibroBiologics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: low
  FibroBiologics, Inc. (FBLG) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. FibroBiologics, Inc. filed a 10-Q report for the period ending March 3

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX